Loading
A phase 2 trial of Cisplatin in head and neck squamous cell carcinoma, run by EpicentRx, Inc., active and no longer recruiting.
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer is a phase 2 interventional study registered as NCT05966194 by EpicentRx, Inc., with 216 participants enrolled, started 2024-04-02 and due to reach its primary completion in 2027-07-01. Interventions recorded: RRx-001, Intensity Modulated Radiation Therapy (IMRT) and Cisplatin for injection 100 mg/m2.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Oral cavity cancer (mouth and tongue), Platinum agents, Cisplatin, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Platinum agents, Cisplatin, Head and neck squamous cell carcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Oropharyngeal cancer (tonsil and base of tongue), Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares EpicentRx and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/